Yhdysvallat - englanti - NLM (National Library of Medicine)

henry schein, inc. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - this drug is contraindicated in patients previously found to be hypersensitive to lincomycin or clindamycin.

Kanada - englanti - Health Canada

avir pharma inc. - sincalide - powder for solution - 5mcg - sincalide 5mcg - gallbladder function

Yhdysvallat - englanti - NLM (National Library of Medicine)

maia pharmaceuticals, inc. - sincalide (unii: m03giq7z6p) (sincalide - unii:m03giq7z6p) - sincalide for injection is indicated in adults to: - stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; - stimulate pancreatic secretion in combination with secretin prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; - accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract. sincalide for injection is contraindicated in patients with: - a history of a hypersensitivity reaction to sulfites or sincalide. serious hypersensitivity reactions have included anaphylaxis and anaphylactic shock [see warnings and precautions (5.1), adverse reactions (6)]. - intestinal obstruction. risk summary based on limited human data and mechanism of action, sincalide for inj

Yhdysvallat - englanti - NLM (National Library of Medicine)

fosun pharma usa inc - sincalide (unii: m03giq7z6p) (sincalide - unii:m03giq7z6p) - sincalide for injection is indicated in adults to: - stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; - stimulate pancreatic secretion in combination with secretin prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; - accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract. sincalide for injection is contraindicated in patients with: - a history of a hypersensitivity reaction to sincalide. serious hypersensitivity reactions have included anaphylaxis and anaphylactic shock [see warnings and precautions (5.1), adverse reactions (6)]. - intestinal obstruction. risk summary based on limited human data and mechanism of action, sincalide for

Yhdysvallat - englanti - NLM (National Library of Medicine)

fresenius kabi usa, llc - sincalide (unii: m03giq7z6p) (sincalide - unii:m03giq7z6p) - sincalide for injection is indicated in adults to: - to stimulate gallbladder contraction, as may be assessed by various methods of diagnostic imaging, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; - to stimulate pancreatic secretion in combination with secretin prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; - to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract. sincalide for injection is contraindicated in patients with: - a history of hypersensitivity to sulfites or sincalide. serious hypersensitivity reactions have included anaphylaxis and anaphylactic shock [see warnings and precautions (5.1), adverse reactions (6)] . - intestinal obstruction. risk summary based on limited human data and mechanism of action, sincalide may cause preterm labor or spontaneous abortion [see warnings and precautions (5.4)]. available data with sincalide for injection are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal embryo-fetal development studies in which sincalide was administered to hamsters and rats during the period of organogenesis, no effects were seen at doses comparable to the maximum recommended clinical dose on a mg/kg basis. however, in a prenatal development study in which rats were administered sincalide during organogenesis through parturition, decreased weight gain and developmental delays were observed at a dose 122 times higher than the maximum recommended human dose based on body surface area. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data animal data there were no effects on embryo-fetal development in hamsters when sincalide was administered subcutaneously at 250 or 750 ng/kg during organogenesis (gestation days 7 to 13) at doses up to 0.8 times the maximum recommended dose of 120 ng/kg on a body surface area basis. no effects on embryo-fetal development were observed in sprague-dawley rats at subcutaneous doses of 250, 450, or 750 ng/kg from gestation days 6 to16, representing 1.0 time the maximum recommended human dose on a body surface area basis. in a separate study at a higher dose of 90 mcg/kg administered subcutaneously to cfy rats from gestation day 10 through parturition (representing 122 times the maximum recommended human dose on a body surface area basis), offspring showed decreased growth, behavioral changes, and developmental delays. risk summary there are no data regarding the presence of sincalide in human or animal milk, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for sincalide for injection and any potential adverse effect on the breastfed infant from sincalide for injection or from the underlying condition. the safety and effectiveness in pediatric patients have not been established. clinical studies of sincalide for injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Uusi-Seelanti - englanti - Ministry for Primary Industries

zoetis new zealand limited - spectinomycin sulphate; lincomycin hydrochloride - spectinomycin sulphate 445 g/kg; lincomycin hydrochloride 222 g/kg - antibiotic

Yhdysvallat - englanti - NLM (National Library of Medicine)

zoetis inc. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincocin products are indicated in infections caused by gram-positive organisms which are sensitive to its action, particularly streptococci and staphylococci. the drug has proven effective in eradicating causative organisms in most of the common upper respiratory tract infections, in septicemia, and in infections of the skin and adjoining tissues. systemic therapy with lincocin has been shown to be of benefit in many animals with pustular dermatitis. as with all antibiotics, in vitro sensitivity studies should be performed before lincocin is utilized as sole antibiotic therapy. lincocin has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and sensitive to lincomycin. the drug may be administered in combination therapy with other antimicrobial agents when indicated. no serious hypersensitivity reactions have been reported and many animals have received lincocin repeatedly without developing evidence of hypersensitivity. lincocin has demonstrated e

Yhdysvallat - englanti - NLM (National Library of Medicine)

aspen veterinary resources, ltd. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin injectable is indcated fot he treatmen of infectious forms of arthritis caused by organisms sensitive to its activity. this includes most of the organisms responsible for the various infectious arthritides in swine, such as staphylococci, streptococci, erysipelothrix and mycoplasma ssp . it is also indicated for the treatment of mycoplasma pneumonia. as with all drugs, the use of lincomycin injectable is contraindicated in animals previously found to be hypersensitive to the drug. 

Belgia - englanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - lincomycin hydrochloride - eq. lincomycin 500 mg - capsule, hard - 500 mg - lincomycin hydrochloride - lincomycin

Belgia - englanti - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - lincomycin hydrochloride - eq. lincomycin 50 mg/ml - syrup - 250 mg/5 ml - lincomycin hydrochloride - lincomycin